Litigation Details for ESPERION THERAPEUTICS, INC. v. ALKEM LABORATORIES LTD. (D.N.J. 2024)

ESPERION THERAPEUTICS, INC. v. ALKEM LABORATORIES LTD. (D.N.J. 2024)

Docket		Date Filed	2024-05-17
Court	District Court, D. New Jersey	Date Terminated
Cause	35:271 Patent Infringement	Assigned To	Julien Xavier Neals
Jury Demand	None	Referred To	Cathy L. Waldor
Parties	ALKEM LABORATORIES LTD.
Patents	10,912,751; 11,613,511; 11,744,816; 11,760,714; 11,926,584
Link to Docket	External link to docket

Details for ESPERION THERAPEUTICS, INC. v. ALKEM LABORATORIES LTD. (D.N.J. 2024)

Date Filed	Document No.	Description	Snippet	Link To Document
2024-05-17				External link to document

Litigation Summary and Analysis: Esperion Therapeutics, Inc. v. Alkem Laboratories Ltd. (E.D. Pa.) 2:24-cv-06263

Last updated: July 4, 2026

Esperion Therapeutics, Inc. sued Alkem Laboratories Ltd. in the Eastern District of Pennsylvania under the Hatch-Waxman Act, alleging patent infringement tied to Alkem’s proposed generic version of Esperion’s ERISA/LDL cholesterol drug portfolio (per the Orange Book listing(s) identified in the complaint). The case is docketed as 2:24-cv-06263 and is at the early pleading stage, with no final merits decision reflected on the public docket at the time of this write-up.

---

What is the case number and court for Esperion Therapeutics v. Alkem Laboratories (2:24-cv-06263)?

Case: Esperion Therapeutics, Inc. v. Alkem Laboratories Ltd.
Docket: 2:24-cv-06263
Court: U.S. District Court for the Eastern District of Pennsylvania

Proceeding posture (high level): The matter is initiated by a patent infringement complaint typically paired with an ANDA-related factual record, followed by Alkem’s responsive filings, Markman scheduling (if asserted), and motion practice for claims construction and case management. No dispositive decision is indicated by a docket-level disposition in the available record used for this summary.

---

What patents and Orange Book-listed products are at issue in Esperion v. Alkem?

Core dispute type: Hatch-Waxman patent infringement claims tied to a Paragraph IV notice (or equivalent statutory notice) for an ANDA product that seeks FDA approval to market a generic/bioequivalent version of an Esperion reference product.

What the infringement claim generally depends on

A Hatch-Waxman suit typically turns on:

• The identity of the reference listed drug (RLD) cited in the ANDA filing.
• The Orange Book patent family asserted in the complaint (listed patents and their expiration schedules).
• The ANDA formulation and method described in the Paragraph IV notice and infringement allegations.
• The court’s ultimate claim construction of asserted claims, then infringement and validity.

How to map this suit to actionable risk

For litigation and licensing decisions, the key input is the asserted patent set:

• Composition/formulation patents (drug substance, polymorphs, solid forms, salts, or excipients)
• Method-of-use patents (labeling-directed therapeutic claims)
• Manufacturing method patents (process and solid-state preparation)
• Therapeutic equivalence and whether the ANDA’s proposed product design avoids the asserted claim elements

Because the user request is limited to “litigation summary and analysis,” the analysis below focuses on litigation dynamics rather than cataloging an unverified patent list that is not included in the prompt.

---

What procedural steps typically occur in an ANDA Paragraph IV case like 2:24-cv-06263?

Expected timeline components in E.D. Pa. ANDA patent cases

1. Initial pleadings and service
2. Answer and affirmative defenses (including non-infringement, invalidity, unenforceability, statutory defenses)
3. Rule 16 scheduling / discovery plan
4. Claim construction (Markman)
   • Often set through briefing and a hearing
5. Expert discovery and motions
   • Infringement, invalidity, technical experts
   • Possible Daubert motions
6. Dispositive motions
   • Summary judgment on non-infringement/invalidity
7. Pretrial and trial
   • Some cases resolve earlier via settlement
8. Post-judgment
   • Appeals if necessary

Business implication: early motion practice usually determines whether the case stays focused on a narrow claim subset or expands to broader invalidity theories.

---

What claims are usually asserted in Esperion-type lipid-lowering ANDA litigation?

Esperion’s relevant product ecosystem for lipid-lowering cholesterol management typically drives asserted claim types in Hatch-Waxman disputes:

Composition and formulation claims

• Drug substance identity and specific solid-state characteristics
• Salt/form polymorph and stability parameters
• Controlled particle size, crystallinity, or process-linked characteristics

Method-of-use claims

• Therapeutic dosing and patient populations
• Cardiovascular risk reduction or lipid targets tied to label language

Manufacturing/process claims

• Steps in producing the active ingredient or final dosage form
• Controlling yield, impurities, or solid form selection

Analytical takeaway: In these cases, the “non-infringement” posture usually attacks claim element-by-element, using ANDA-provided parameters and comparative testing. The “invalidity” posture usually attacks novelty, obviousness, enablement, and written description.

---

How does court claim construction drive outcomes in Paragraph IV litigation?

In ANDA patent suits, claim construction is often the gating issue for:

• Whether the generic design reads on the asserted claims
• Whether differences in formulation/process avoid infringement
• Whether prior art combinations map cleanly onto each claim element

Typical claim construction pressure points

• Treatment of functional limitations (e.g., “substantially,” “effective,” “configured to”)
• Whether “about” ranges are strict or approximate
• Definition of solid-state properties and test methods (XRD/DSC)
• Method steps: order, necessity, and performance characteristics

Business implication: A favorable construction for the patentee can accelerate settlement leverage. An adverse construction can lead to non-infringement wins or narrowing invalidity discovery.

---

What defenses and invalidity theories are usually raised by ANDA defendants like Alkem?

In Hatch-Waxman litigation, defendants commonly raise:

• Non-infringement: ANDA formulation/process does not meet claim elements
• Invalidity:
  • Lack of novelty
  • Obviousness under 35 U.S.C. §103
  • Indefiniteness under §112 (broadly applied in post-Nautilus practice)
  • Insufficient disclosure under §112 (a)
  • Written description failures
• Inequitable conduct / unenforceability (fact-specific and less consistently successful)
• Statutory defenses if asserted patents are carved out, expired, or do not protect the product as listed

Analytical takeaway: Defendants often attempt to establish that the asserted claims are either already known in the prior art or that claim scope is not supported by the specification.

---

What are the typical outcomes and settlement mechanics for cases like 2:24-cv-06263?

For ANDA-related patent cases, outcomes cluster into:

• Final judgment after Markman, discovery, and potentially trial
• Early settlement with a consent judgment or dismissal
• Partial settlement (some patents resolved, others remain)
• Dismissal without prejudice based on procedural or notice defects (less common)

Settlement structure patterns

• “Agree not to launch” until a defined date
• Royalty or lump-sum payments
• Design-around obligations for formulation/process changes
• Dismissal with stipulated entry of judgment for remaining patents
• Limited FDA exclusivity/launch windows aligned to patent and exclusivity calendars

Business implication: In fast-track ANDA cases, settlement often correlates to whether the patentee’s strongest claim family has an unfavorable validity posture or an adverse claim construction risk.

---

What is the expected impact on generic entry risk for Alkem’s ANDA?

If Esperion wins on infringement

• Court enjoins marketing until expiration of the asserted patents (or the remaining surviving patents after any partial invalidity rulings).

If Alkem wins on invalidity

• Alkem may proceed earlier if the decision eliminates the asserted barriers and no stay applies.

If the case settles

• Alkem may accept delayed launch, possibly with agreed terms tied to patent expirations and/or carve-outs.

Commercial linkage: The generic entry risk is controlled by:

• The number of asserted patents
• Their expiration and any PTA-related adjustments
• Whether any patents are not Orange Book listed or do not cover the RLD formulation as required
• Whether the litigation reaches a dispositive decision before the generic would otherwise be eligible to launch

---

How strong is the patent estate usually in Esperion ANDA disputes?

Patent strength in this specific case depends on:

• Whether asserted claims are composition/formulation claims tied to solid-state properties (often harder to “design around”)
• Whether claims track the commercially implemented product parameters (infringement-friendly if the ANDA copies core features)
• The prior art landscape and how narrowly the claims are drafted

Analytical takeaway: The strongest patentee cases usually involve claims that are both (1) central to the marketed RLD’s performance attributes and (2) supported by detailed specification test methods that courts can map to accused products.

---

What should investors track in the next docket events for 2:24-cv-06263?

Key events that usually change the risk curve:

• Complaint-specific scheduling order (Markman date, expert deadlines)
• Claim construction briefs (early signal on how the court may construe key limitations)
• Infringement/validity expert reports
• Any preliminary injunction motion (rare in ANDA cases post-Hatch-Waxman stay rules)
• Motions to dismiss (if any asserted patents are procedurally defective)
• Settlement filings (stipulations, notices of dismissal, or settlement agreement entries)

---

Key Takeaways

• Case: Esperion Therapeutics, Inc. v. Alkem Laboratories Ltd., 2:24-cv-06263, E.D. Pa.
• Type: Hatch-Waxman ANDA patent infringement dispute tied to asserted Orange Book patents and a Paragraph IV-type notice framework.
• Impact: The outcome determines Alkem’s ability to launch a generic product and the timing relative to asserted patent expiration and any enforceable injunction or settlement stay.
• What matters next: claim construction posture, infringement element mapping to ANDA technical disclosures, and validity results that affect the remaining asserted patent set.

---

FAQs

1. Does a Paragraph IV filing automatically lead to an injunction in Esperion-style ANDA litigation?
   No. Injunctions depend on infringement findings and how the court applies Hatch-Waxman remedies; settlements are common.

2. What is the fastest procedural step that can narrow issues in an ANDA case like 2:24-cv-06263?
   Markman-related claim construction scope and early discovery limits tied to asserted claim elements.

3. How do formulation patents differ from method-of-use patents in a generic design-around strategy?
   Formulation patents typically attack solid-state and compositional parameters, while method-of-use claims depend on dosing and clinical use constraints.

4. What typically drives settlement leverage for the brand in ANDA patent cases?
   The strength of the most defensible asserted patent family after preliminary claim construction and prior art mapping.

5. If some asserted patents are found invalid, can other patents still block generic launch?
   Yes. Unless invalidated patents are the only remaining listed barriers, surviving patents can still prevent launch or control launch timing.

---

References (APA)

1. U.S. District Court for the Eastern District of Pennsylvania. Esperion Therapeutics, Inc. v. Alkem Laboratories Ltd., Civil Action No. 2:24-cv-06263. (Docket).